Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Weight-loss drugs helped Dimpy Kapoor shed 15 kg and reclaim her life. Ozempic and Mounjaro are a lifeline for diabetics and ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of alcohol ...

Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

we loaded a sample photo in each editing app and experimented with it, getting a feel for the user experience and looking for any pain points. We took stock of what features were available to free ...